European multi-center study suggests PCA3 test more accurate for prostate cancer

    Ticker Symbol: CUR

    QUEBEC CITY, March 26 /CNW Telbec/ - DiagnoCure (TSX: CUR), today
announced that preliminary results from an on-going multi-center study
presented last week by independent researchers in Europe indicate that a new
Gen-Probe (NASDAQ:   GPRO) PCA3-based test for prostate cancer yielded greater
diagnostic accuracy than the free prostate specific antigen (PSA) test on men
with previous negative biopsy.
    The information was contained in a poster presentation at the European
Association of Urology meeting in Berlin last week, by Dr. Alexander Haese of
the University Medical Center Eppendorf, in Hamburg, Germany. The data were
from 199 men enrolled in the seven hospital study in Europe. All of them
previously had a negative prostate biopsy. In the study, all respondents
received a repeat biopsy, Gen-Probe's PROGENSA PCA3(TM) molecular urine test,
a serum test for total PSA and a serum test for free PSA.
    Based on the interim analysis presented at the EAU meeting, the
researchers concluded that the PROGENSA PCA3(TM) assay was better than free
PSA at predicting the result of the repeat biopsy. They reported the PCA3 test
had a specificity of 73% in the study, compared to only 16% for free PSA. The
researchers also said that higher PCA3 scores correlated with a greater
likelihood of a positive repeat biopsy. For example, men with an elevated PCA3
score had a 41% likelihood of having a positive repeat biopsy, while men with
a low PCA3 score had only a 16% likelihood.
    Another promising study presented by Gen-Probe and independent
researchers at the EAU meeting showed that the PCA3 score did not correlate
with the size of the prostate gland. Importantly, previous research has
suggested that the PCA3 score does correlate with the size of the prostate
tumor. These findings reflect the fact that PCA3 overexpression is highly
specific to prostate cancer. By comparison, serum PSA may be elevated due to a
number of benign conditions, resulting in "false positive" results and
unnecessary biopsies. In fact, as many as three-quarters of men suspected to
have cancer based on PSA testing actually have non-cancerous conditions, such
as benign prostatic hyperplasia (BPH).
    "These studies are very important milestones in the commercialization of
our PCA3 gene," said John Schafer, President and CEO of DiagnoCure. "These
study results confirm that the gene has the potential to provide critical
information to physicians and their patients for the management of prostate
cancer, which is key to achieving successful commercialization."
    These and other studies represent the most recent wave of independent
research on the effectiveness of the PCA3 gene as a biomarker for prostate
cancer since Gen-Probe's PROGENSA PCA3(TM) test was CE marked for
commercialization in Europe in November 2006. Laboratories in Europe currently
offering the test include NovioGendix (Nijmegen, the Netherlands), the Centre
of Applied Molecular Technologies Université catholique de Louvain (Bruxelles,
Belgium), Medi-Lab (Manchester, UK), the Doctors Laboratory (London, UK),
Labor Limbach (Heidelberg, Germany), and LCL (Seine, France). The test is not
approved for marketing in the United States.
    The PCA3 gene was discovered by Dr. Marion Bussemakers while working with
Dr. Jack Schalken at the University of Nijmegen in the Netherlands and in the
laboratory of Dr. William Isaacs at Johns Hopkins University in Baltimore,
Maryland. DiagnoCure is the exclusive worldwide licensee for all diagnostic
and therapeutic applications of the gene and granted Gen-Probe exclusive
worldwide prostate cancer diagnostic rights to the PCA3 gene in November of

    About DiagnoCure

    DiagnoCure specializes in the development, production and
commercialization of molecular diagnostics for the detection and management of
cancer. Its first test, ImmunoCyt(TM) / uCyt+(TM) for bladder cancer, is
distributed worldwide. In 2003, the Company entered into a strategic alliance
with Gen-Probe (NASDAQ:   GPRO) for the development and commercialization of a
second generation PCA3-based diagnostic test for prostate cancer. This test is
now available in analyte specific reagent (ASR) format in the U.S. as well as
in Europe with full CE Mark. The Company plans to expand its product
portfolio, namely in prostate, lung and other cancers. In addition to its own
research, the Company intends to acquire or in-license promising cancer
biomarkers from both academic and commercial institutions. Additional
information can be found at

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects and future revenues are based on
management expectations. In addition, the reader is referred to the applicable
general risks and uncertainties described in DiagnoCure's most recent Annual
Information Form under the heading "Risk Factors". DiagnoCure undertakes no
obligation to publicly update or revise any forward-looking statements
contained herein.
    %SEDAR: 00003671EF

For further information:

For further information: Thom Skinner, Chief Financial Officer,
DiagnoCure Inc., (418) 527-6100,

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890